what this node claims
AlphaFold metrics / OXTR
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
53%
low debt pressure
21%
79%structureusable
pLDDT 78.62
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 78.62
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 78.62
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
389 residues / min 24.28 / max 98.81 / source alphafold db
Very high
51.9%
202 residues / >=90
Confident
19.8%
77 residues / 70-89
Low
11.3%
44 residues / 50-69
Very low
17.0%
66 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 389 of 389 residues.
- residues 346-389 / mean 42.63
- residues 1-34 / mean 34.62
- residues 243-264 / mean 56.55
- residues 306-314 / mean 63.75
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.